http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

"Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 * Ischemic bowel disease [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4"

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_3393 DOID_3393

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00953 drugbank:DB00953

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-08-23T16:05:19.392Z

http://purl.org/np/RAal1_aAty... RAal1_aAty

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/MedicalContraindication MedicalContraindication

Leoni Bücken

2021-08-23T16:05:19.392Z